Business Context and Reporting Period
This Form 8-K was filed by Integrity Applications, Inc. (not Glucotrack, Inc.) on June 8, 2017, reporting events occurring on June 7, 2017. The registrant is a Delaware corporation headquartered in Ashdod, Israel.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change is the appointment of David Podwalski as Chief Commercial Officer, effective June 26, 2017. This appointment includes a new employment agreement with specific compensation terms.
Management Commentary and Compensation Details
- Base Salary: $240,000 per year.
- Sign-on Bonus: $25,000, payable on the six-month anniversary of the effective date, contingent on continued employment.
- Performance Bonus: Target opportunity of 25% of base salary. The range is 20% (minimum) to 37.5% (maximum) based on performance criteria achievement.
- Equity Grant: Initial stock option to purchase shares equal to 1% of total fully diluted shares underlying Series C Units sold as of the effective date. Exercise price is $4.50 per share or fair market value on the grant date, whichever is greater. Vesting occurs monthly over three years.
- Termination: Company may terminate with 90 days' notice; employee may terminate with 30 days' notice. Immediate termination for Cause is permitted without severance.
Investor Verification Checklist
- Verify the exact number of "Series C Units" sold as of June 26, 2017, to calculate the specific share count of the 1% option grant.
- Confirm the fair market value of the common stock on the grant date to determine the final exercise price.
- Review the specific performance criteria defined in the Employment Agreement to assess the likelihood of bonus payouts.
- Check subsequent filings for any changes to the executive team or compensation structure.